Girard Partners LTD. Has $7.96 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Girard Partners LTD. trimmed its position in Johnson & Johnson (NYSE:JNJ) by 8.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 61,507 shares of the company’s stock after selling 5,418 shares during the quarter. Johnson & Johnson comprises approximately 1.5% of Girard Partners LTD.’s holdings, making the stock its 17th largest position. Girard Partners LTD.’s holdings in Johnson & Johnson were worth $7,957,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Phocas Financial Corp. raised its stake in Johnson & Johnson by 999,928.6% during the 2nd quarter. Phocas Financial Corp. now owns 125,173,583 shares of the company’s stock valued at $1,743,000 after purchasing an additional 125,161,066 shares during the last quarter. Nuveen Asset Management LLC raised its stake in Johnson & Johnson by 5,447.1% during the 2nd quarter. Nuveen Asset Management LLC now owns 16,924,656 shares of the company’s stock valued at $2,357,266,000 after purchasing an additional 16,619,550 shares during the last quarter. Thoroughbred Financial Services LLC raised its stake in Johnson & Johnson by 14,147.0% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock valued at $401,425,000 after purchasing an additional 3,986,071 shares during the last quarter. Renaissance Technologies LLC raised its stake in Johnson & Johnson by 145.5% during the 2nd quarter. Renaissance Technologies LLC now owns 4,341,162 shares of the company’s stock valued at $604,637,000 after purchasing an additional 2,572,695 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in Johnson & Johnson by 11.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 20,791,713 shares of the company’s stock valued at $2,895,870,000 after purchasing an additional 2,204,757 shares during the last quarter. Institutional investors and hedge funds own 72.25% of the company’s stock.

Several equities analysts recently commented on JNJ shares. Zacks Investment Research upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 target price for the company in a research note on Thursday, October 17th. Raymond James cut their target price on shares of Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Sanford C. Bernstein upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 target price for the company in a research note on Friday, October 11th. Wells Fargo & Co cut their target price on shares of Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a research note on Wednesday, October 16th. Finally, Atlantic Securities upgraded shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research note on Wednesday, October 16th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Johnson & Johnson currently has an average rating of “Buy” and a consensus target price of $151.64.

Shares of JNJ stock traded up $1.57 during mid-day trading on Friday, reaching $133.00. The company’s stock had a trading volume of 4,856,974 shares, compared to its average volume of 7,224,392. Johnson & Johnson has a 1-year low of $121.00 and a 1-year high of $148.99. The company has a market cap of $343.25 billion, a P/E ratio of 16.26, a PEG ratio of 2.20 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.00 and a current ratio of 1.26. The firm’s 50-day moving average is $130.83 and its two-hundred day moving average is $134.05.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.00 by $0.12. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The company had revenue of $20.73 billion during the quarter, compared to analysts’ expectations of $20.14 billion. During the same quarter in the prior year, the company posted $2.05 EPS. The business’s revenue was up 1.9% on a year-over-year basis. Sell-side analysts anticipate that Johnson & Johnson will post 8.65 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.86%. The ex-dividend date is Monday, November 25th. Johnson & Johnson’s dividend payout ratio is 46.45%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: What is Call Option Volume?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit